Abstract
In December 2009, Holista CollTech Ltd. was established as a biotechnology company and its core business was the production of ovine collagen and Kacip Fatimah extracts. The ovine collagen was used mainly in a broad range of food, health supplements, cosmetics, and medical products, while Kacip Fatimah extracts were ingredients for food and supplements products. Holista CollTech's corporate vision was to be a global player in the multi-billion dollar collagen and herb extract markets. However, it faced fierce competition in the collagen market which was already dominated by a number of large multinational firms, and in the herb extract market in which competition was becoming increasingly intense due to the rising number of imitators. This was a challenging situation for Holista CollTech Ltd. since these competitions could prevent the company from achieving its objective to increase its control in these two markets. This case provides the opportunity to discuss Holista's competitive environment and internal elements. The case analyst will recommend appropriate strategies to the newly appointed Chief Executive Officer.
Original language | English |
---|---|
Pages (from-to) | 187-232 |
Number of pages | 46 |
Journal | Asian Case Research Journal |
Volume | 14 |
Issue number | 2 |
DOIs | |
Publication status | Published - Dec 2010 |
Fingerprint
ASJC Scopus subject areas
- Business, Management and Accounting(all)
Cite this
Holista CollTech : Directions for focused growth. / Rizal, Adriana Mohd; Adham, Khairul Akmaliah; Said, Mohd Fuaad.
In: Asian Case Research Journal, Vol. 14, No. 2, 12.2010, p. 187-232.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Holista CollTech
T2 - Directions for focused growth
AU - Rizal, Adriana Mohd
AU - Adham, Khairul Akmaliah
AU - Said, Mohd Fuaad
PY - 2010/12
Y1 - 2010/12
N2 - In December 2009, Holista CollTech Ltd. was established as a biotechnology company and its core business was the production of ovine collagen and Kacip Fatimah extracts. The ovine collagen was used mainly in a broad range of food, health supplements, cosmetics, and medical products, while Kacip Fatimah extracts were ingredients for food and supplements products. Holista CollTech's corporate vision was to be a global player in the multi-billion dollar collagen and herb extract markets. However, it faced fierce competition in the collagen market which was already dominated by a number of large multinational firms, and in the herb extract market in which competition was becoming increasingly intense due to the rising number of imitators. This was a challenging situation for Holista CollTech Ltd. since these competitions could prevent the company from achieving its objective to increase its control in these two markets. This case provides the opportunity to discuss Holista's competitive environment and internal elements. The case analyst will recommend appropriate strategies to the newly appointed Chief Executive Officer.
AB - In December 2009, Holista CollTech Ltd. was established as a biotechnology company and its core business was the production of ovine collagen and Kacip Fatimah extracts. The ovine collagen was used mainly in a broad range of food, health supplements, cosmetics, and medical products, while Kacip Fatimah extracts were ingredients for food and supplements products. Holista CollTech's corporate vision was to be a global player in the multi-billion dollar collagen and herb extract markets. However, it faced fierce competition in the collagen market which was already dominated by a number of large multinational firms, and in the herb extract market in which competition was becoming increasingly intense due to the rising number of imitators. This was a challenging situation for Holista CollTech Ltd. since these competitions could prevent the company from achieving its objective to increase its control in these two markets. This case provides the opportunity to discuss Holista's competitive environment and internal elements. The case analyst will recommend appropriate strategies to the newly appointed Chief Executive Officer.
UR - http://www.scopus.com/inward/record.url?scp=79952065471&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952065471&partnerID=8YFLogxK
U2 - 10.1142/S0218927510001386
DO - 10.1142/S0218927510001386
M3 - Article
AN - SCOPUS:79952065471
VL - 14
SP - 187
EP - 232
JO - Asian Case Research Journal
JF - Asian Case Research Journal
SN - 0218-9275
IS - 2
ER -